{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:27:24Z","timestamp":1760027244299},"reference-count":23,"publisher":"Academy of Managed Care Pharmacy","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMCP"],"published-print":{"date-parts":[[2015,1,1]]},"DOI":"10.18553\/jmcp.2015.21.1.88","type":"journal-article","created":{"date-parts":[[2016,2,16]],"date-time":"2016-02-16T18:21:21Z","timestamp":1455646881000},"page":"88-99","source":"Crossref","is-referenced-by-count":5,"title":["Impact of Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccine Use in Wound Management on Health Care Costs and Pertussis Cases"],"prefix":"10.18553","volume":"21","author":[{"given":"Sandra E.","family":"Talbird","sequence":"first","affiliation":[{"name":"Director, Health Economics, RTI Health Solutions, Research Triangle Park, North Carolina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Graham","sequence":"additional","affiliation":[{"name":"Associate Director, Health Economics, RTI Health Solutions, Research Triangle Park, North Carolina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josephine","family":"Mauskopf","sequence":"additional","affiliation":[{"name":"Vice President, Health Economics, RTI Health Solutions, Research Triangle Park, North Carolina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Masseria","sequence":"additional","affiliation":[{"name":"Health Outcomes Manager, NAVD Health Outcomes, GlaxoSmithKline, King of Prussia, Pennsylvania."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girishanthy","family":"Krishnarajah","sequence":"additional","affiliation":[{"name":"Therapy Area Head, NAVD Health Outcomes, GlaxoSmithKline, King of Prussia, Pennsylvania."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7818","reference":[{"issue":"17","key":"B1","first-page":"1","volume":"55","author":"Kretsinger K","year":"2006","journal-title":"MMWR Recomm Rep"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2006.10.015"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1086\/425006"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1086\/514776"},{"issue":"25","key":"B7","first-page":"468","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis871"},{"issue":"4","key":"B11","first-page":"468","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7326\/M13-2332"},{"issue":"241","key":"B13","first-page":"1","volume":"10","author":"Chen LH","year":"2009","journal-title":"Vital Health Stat 10"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2006.10.016"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000160918.72953.51"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000166160.23976.35"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067260"},{"key":"B18","unstructured":"Acosta A. Cost-effectiveness of pertussis vaccine substitution for tetanus booster in prevention of pertussis in adults 65 years and older. Presentation to the Advisory Committee on Immunization Practices (ACIP). February 22, 2012. Atlanta, GA: US Department of Health and Human Services, CDC; 2012."},{"key":"B19","unstructured":"Krishnarajah G. Cost-effectiveness analysis of Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed) among individuals \u2265 65 years of age in prevention of pertussis. Presentation to the Advisory Committee on Immunization Practices (ACIP). February 22, 2012. Atlanta, GA: US Department of Health and Human Services, CDC; 2012."},{"key":"B20","unstructured":"Liang J. Considerations for a second Tdap for the general population. Pertussis Vaccines Work Group. Centers for Disease Control and Prevention. June 19, 2013."},{"issue":"53","key":"B22","first-page":"1","volume":"59","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1086\/319853"},{"issue":"10","key":"B24","first-page":"1","volume":"59","author":"Mini\u00f1o AM","year":"2011","journal-title":"Natl Vital Stat Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-5-57"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.08.2291"},{"issue":"4","key":"B30","first-page":"73","volume":"51","author":"Centers for Disease Control and Prevention","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B31","volume-title":"The Essential RBRVS: A Comprehensive Listing of RBRVS Values for CPT and HCPCS Codes","author":"Ingenix","year":"2012"}],"container-title":["Journal of Managed Care & Specialty Pharmacy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T14:02:45Z","timestamp":1703858565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmcp.org\/doi\/10.18553\/jmcp.2015.21.1.88"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1,1]]}},"alternative-id":["10.18553\/jmcp.2015.21.1.88"],"URL":"https:\/\/doi.org\/10.18553\/jmcp.2015.21.1.88","relation":{},"ISSN":["2376-0540","2376-1032"],"issn-type":[{"value":"2376-0540","type":"print"},{"value":"2376-1032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,1]]}}}